BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Medium (6M)
Nirmal Bang Initiates Coverage On Pfizer With 'Accumulate' Rating
Nirmal Bang expects the drug makers earnings to register a compounded annual growth rate of 9 per cent over FY18- FY21, primarily driven by Prevnar 13, Becosules and Corex.